Pharmacotherapy remains the foundation of psychiatric treatment, yet medication-centered algorithms frequently fail to deliver sustained remission, particularly in depression, obsessive-compulsive disorder, and neurodevelopmental populations. Neuromodulation has traditionally been reserved for later lines of care; however, emerging evidence suggests a rapidly expanding role—earlier in illness course, in adolescents, and in combination with neuroplasticity-enhancing interventions.
This session provides a concise critique of the limitations of medication-only paradigms, followed by a high-level overview of the current neuromodulation landscape, including TMS, ECT, VNS, and DBS. The majority of the session will focus on future-facing innovations and breakthrough therapies, including first-line and accelerated TMS protocols, adolescent and OCD-specific applications, combination approaches with neuroplasticity-enhancing agents, at-home neuromodulation, transcranial direct current stimulation (tDCS), and emerging indications beyond major depressive disorder.
Through evidence-informed discussion and real-world clinical examples, attendees will gain a forward-looking framework to understand where neuromodulation is headed, how these advances may reshape treatment algorithms, and how to responsibly counsel patients amid rapidly evolving options.